Angela F. el Hebieshy, Zacharias Wijfjes, Camille M. Le Gall, Jim Middelburg, Kim E. de Roode, Felix L. Fennemann, Marjolein Sluijter, Thorbald van Hall, Douwe J. Dijkstra, Leendert A. Trouw, Floris J. van Dalen, Andrea Rodgers Furones, Johan M. S. van der Schoot, Ian Derksen, Hans de Haard, Bas van der Woning, Cami M. P. Talavera Ormeño, Bjorn R. van Doodewaerd, Carl G. Figdor, Gerbrand J. van der Heden van Noort, Paul W. H. I. Parren, Sandra Heskamp, Huib Ovaa, Martijn Verdoes, Ferenc A. Scheeren
{"title":"Site-directed multivalent conjugation of antibodies to ubiquitinated payloads","authors":"Angela F. el Hebieshy, Zacharias Wijfjes, Camille M. Le Gall, Jim Middelburg, Kim E. de Roode, Felix L. Fennemann, Marjolein Sluijter, Thorbald van Hall, Douwe J. Dijkstra, Leendert A. Trouw, Floris J. van Dalen, Andrea Rodgers Furones, Johan M. S. van der Schoot, Ian Derksen, Hans de Haard, Bas van der Woning, Cami M. P. Talavera Ormeño, Bjorn R. van Doodewaerd, Carl G. Figdor, Gerbrand J. van der Heden van Noort, Paul W. H. I. Parren, Sandra Heskamp, Huib Ovaa, Martijn Verdoes, Ferenc A. Scheeren","doi":"10.1038/s41551-024-01342-z","DOIUrl":null,"url":null,"abstract":"<p>Antibody conjugates are the foundation of a wide range of diagnostic and therapeutic applications. Although many antibody-conjugation techniques are robust and efficient, obtaining homogeneous multimeric conjugation products remains challenging. Here we report a modular and versatile technique for the site-directed multivalent conjugation of antibodies via the small-protein ubiquitin. Specifically, multiple ubiquitin fusions with antibodies, antibody fragments, nanobodies, peptides or small molecules such as fluorescent dyes can be conjugated to antibodies and nanobodies within 30 min. The technique, which we named ‘ubi-tagging’, allowed us to efficiently generate a bispecific T-cell engager as well as nanobodies conjugated to dendritic-cell-targeted antigens that led to potent T-cell responses. Using both recombinant ubi-tagged proteins and synthetic ubiquitin derivatives allows for the iterative, site-directed and multivalent conjugation of antibodies and nanobodies to a plethora of molecular moieties.</p>","PeriodicalId":19063,"journal":{"name":"Nature Biomedical Engineering","volume":"1 1","pages":""},"PeriodicalIF":26.8000,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Biomedical Engineering","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1038/s41551-024-01342-z","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0
Abstract
Antibody conjugates are the foundation of a wide range of diagnostic and therapeutic applications. Although many antibody-conjugation techniques are robust and efficient, obtaining homogeneous multimeric conjugation products remains challenging. Here we report a modular and versatile technique for the site-directed multivalent conjugation of antibodies via the small-protein ubiquitin. Specifically, multiple ubiquitin fusions with antibodies, antibody fragments, nanobodies, peptides or small molecules such as fluorescent dyes can be conjugated to antibodies and nanobodies within 30 min. The technique, which we named ‘ubi-tagging’, allowed us to efficiently generate a bispecific T-cell engager as well as nanobodies conjugated to dendritic-cell-targeted antigens that led to potent T-cell responses. Using both recombinant ubi-tagged proteins and synthetic ubiquitin derivatives allows for the iterative, site-directed and multivalent conjugation of antibodies and nanobodies to a plethora of molecular moieties.
期刊介绍:
Nature Biomedical Engineering is an online-only monthly journal that was launched in January 2017. It aims to publish original research, reviews, and commentary focusing on applied biomedicine and health technology. The journal targets a diverse audience, including life scientists who are involved in developing experimental or computational systems and methods to enhance our understanding of human physiology. It also covers biomedical researchers and engineers who are engaged in designing or optimizing therapies, assays, devices, or procedures for diagnosing or treating diseases. Additionally, clinicians, who make use of research outputs to evaluate patient health or administer therapy in various clinical settings and healthcare contexts, are also part of the target audience.